Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 12:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Short Bowel Syndrome (SBS) Clear all
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study in Infant With SBS

NCT02865122
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
NTRA-9620, Placebo
Drug
Lead sponsor
Elgan Pharma Ltd.
Industry
Eligibility
2 Weeks to 52 Weeks
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Palo Alto, California • Hartford, Connecticut • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 29, 2026, 12:21 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Successful Fiber Food Introduction in Short Bowel Syndrome

NCT06240065
View directory record Official record
Conditions
Short Gut Syndrome
Interventions
Green bean puree
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
4 Months to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 29, 2026, 12:21 AM EDT
Withdrawn Phase 3 Interventional

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

NCT02246816
View directory record Official record
Conditions
Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Gut
Interventions
0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Drug
Lead sponsor
Marathon Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2015 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Not applicable Interventional

Teen and Young Adult Connections for Support From Multidisciplinary Professionals & Peers

NCT02987569
View directory record Official record
Conditions
Short Bowel Syndrome, Malabsorption, Malnutrition
Interventions
mConnect plus mobile connections to multidisciplinary professionals & peers, iPad use plus one mobile connections to multidisciplinary professionals & peers
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
13 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 2 Interventional Results available

Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies

NCT01674478
View directory record Official record
Conditions
Prematurity, Intestine Perforation, Necrotizing Enterocolitis (NEC), Short Bowel Syndrome (SBS)
Interventions
Microlipid with fish oil, Microlipid
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
1 Day to 2 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021

NCT01560403
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
La Jolla, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

NCT03690206
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
glepaglutide, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)

NCT02954458
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
TED, SOC, Syringe, Needle
Drug · Other · Device
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

NCT00172185
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide 0.05 mg/kg/d, teduglutide 0.10 mg/kg/d
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Omaha, Nebraska + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)

NCT00930644
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
La Jolla, California • New York, New York • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 29, 2026, 12:21 AM EDT
Active, not recruiting No phase listed Observational

Registry for Participants With Short Bowel Syndrome

NCT01990040
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
1,806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2032
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 29, 2026, 12:21 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

NCT05018286
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Apraglutide
Drug
Lead sponsor
VectivBio AG
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Naples, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

NCT02682381
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Teduglutide 0.05mg/kg, Teduglutide 0.025 mg/kg, Standard of Care
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
0 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 29, 2026, 12:21 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

NCT07228403
View directory record Official record
Conditions
Short Bowel Syndrome (SBS)
Interventions
Glepaglutide 10 mg
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Rochester, Minnesota • Omaha, Nebraska • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 29, 2026, 12:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

NCT07742735
View directory record Official record
Conditions
Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
Interventions
Apraglutide, Placebo
Drug
Lead sponsor
VectivBio AG
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

NCT00081458
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Placebo, Teduglutide 0.05 mg/kg/d, Teduglutide 0.1 mg/kg/d
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
14
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 29, 2026, 12:21 AM EDT
Terminated Phase 4 Interventional Results available

Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)

NCT00742157
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Growth Hormone
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 78 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

NCT03905707
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
glepaglutide
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Not applicable Interventional

Comparison of Different Oral Rehydration Solutions

NCT02142582
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
WHO ORS, Commercial ORS
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 29, 2026, 12:21 AM EDT
Withdrawn Phase 3 Interventional

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

NCT02242656
View directory record Official record
Conditions
Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Bowel, Short Gut
Interventions
Opium Tincture USP Deodorized
Drug
Lead sponsor
Marathon Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2015 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

NCT01952080
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
1 Year to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

NCT04881825
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Glepaglutide
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 29, 2026, 12:21 AM EDT
Completed Phase 3 Interventional

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

NCT04627025
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
apraglutide
Drug
Lead sponsor
VectivBio AG
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Naples, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 29, 2026, 12:21 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

NCT04775706
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
HM15912 Active, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 29, 2026, 12:21 AM EDT